Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency.
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
This November, African regional members from across the continent including Botswana, Burundi, Cameroon, Ethiopia, France, Ghana, Kenya, Madagascar, Mauritius, Nigeria, Sénégal, South Africa, Uganda and Zimbabwe, convened in…